Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210043 | 0.95 | CA1 (0.43) | CA1CA2CA9CA7ALDH1A1 | |
| SCHEMBL826748 | 0.95 | CA1 (0.43) | CA1CA2CA9CA7ALDH1A1 | |
| SCHEMBL3292581 | 0.90 | CA1 (0.40) | CA1CA2CA9CA7 | |
| SCHEMBL826443 | 0.88 | CA1 (0.48) | CA1CA2CA9CA7ALDH1A1 | |
| SCHEMBL3293856 | 0.86 | CA1 (0.40) | CA1CA2CA9CA7 | |
| SCHEMBL12440878 | 0.83 | CA1 (0.42) | CA1CA2CA9CA7 | |
| SCHEMBL31074798 | 0.83 | CA1 (0.35) | CA1CA2CA9CA7 | |
| SCHEMBL3291599 | 0.83 | CA1 (0.42) | CA1CA2CA9CA7 | |
| SCHEMBL3290672 | 0.82 | CA1 (0.41) | CA1CA2CA9CA7 | |
| SCHEMBL2240677 | 0.80 | CA1 (0.40) | CA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9679761-B2 | Method for preparing a nanoporous ultra-low dielectric thin film including a high-temperature ozone treatment and a nanoporous ultra-low dielectric thin film prepared by the same method | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9679761-B2 | Method for preparing a nanoporous ultra-low dielectric thin film including a high-temperature ozone treatment and a nanoporous ultra-low dielectric thin film prepared by the same method | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20130101825-A1 | METHOD FOR PREPARING A NANOPOROUS ULTRA-LOW DIELECTRIC THIN FILM INCLUDING A HIGH-TEMPERATURE OZONE TREATMENT AND A NANOPOROUS ULTRA-LOW DIELECTRIC THIN FILM PREPARED BY THE SAME METHOD | Industry-University Cooperation Foundation Sogang University (KR) | 2013-04-25 | — | — | US | disclosed |
| US-20130101825-A1 | METHOD FOR PREPARING A NANOPOROUS ULTRA-LOW DIELECTRIC THIN FILM INCLUDING A HIGH-TEMPERATURE OZONE TREATMENT AND A NANOPOROUS ULTRA-LOW DIELECTRIC THIN FILM PREPARED BY THE SAME METHOD | Industry-University Cooperation Foundation Sogang University (KR) | 2013-04-25 | — | — | US | disclosed |
| US-7553819-B2 | Multivalent inhibitors of serum amyloid P component | THERACARB INC. (CA) | 2009-06-30 | — | — | US | disclosed |
| US-20070042936-A1 | Multivalent inhibitors of serum amyloid p component | THERACARB INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2004099173-A1 | MULTIVALENT INHIBITORS OF SERUM AMYLOID P COMPONENT | THERACARB INC. (CA) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042936-A1 | Multivalent inhibitors of serum amyloid p component | IAPP, APP, PRNP | CA1 1663/4885CA2 2153/4885CA9 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.